All Oncology News

Joshua K. Sabari, MD, discusses updates in ADCs in NSCLC.

Matthew Galsky, MD, discusses the significance of the FDA approval of enfortumab vedotin plus pembrolizumab as a first-line regimen in urothelial cancer.

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Bradley Monk, MD, FACOG, FACS has joined the statewide practice.

Investigation of RVT-2001 will be discontinued following an insufficient display of benefit in patients with myelodysplastic syndrome.

Many clinicians have reported a lack of understanding of the FDA approval process and a desire for strong premarket evidence to support these approvals.

Mikkael A. Sekeres, MD, MS, discusses the influence of therapeutic developments and conflicting classification systems on the management of MDS.

The BLA seeking the approval of denileukin diftitox in patients with relapsed/refractory cutaneous T-cell lymphoma was resubmitted to the FDA.

Joshua K. Sabari, MD, explains the utility of ADCs in patients with NSCLC and their benefit in patients with EGFR-, ALK-, or HER2-mutant disease.

The dopamine receptor D2 antagonist ONC201 is under evaluation in patients with H3K27M-mutated diffuse midline glioma in the phase 3 ACTION trial.

The ongoing Flamingo-01 trial continues to investigate GLSI-100 in HER2/neu-positive breast cancer following various holds.

Repotrectinib is under priority review for patients with NTRK-positive locally advanced or metastatic solid tumors and high unmet medical need.

In the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.

Mikkael A. Sekeres, MD, MS, highlights recent approvals and emerging therapeutics in hematologic malignancies discussed by his colleagues.

Catherine C. Coombs, MD, discusses future directions for BTK inhibitors in chronic lymphocytic leukemia and combination therapies in myelofibrosis.

Nicholas P. McAndrew, MD, MSCE, discusses how updated clinical trial findings are shifting the treatment paradigm in HER2-positive metastatic breast cancer.

The FDA has approved irinotecan liposome (Onivyde) with oxaliplatin, fluorouracil, and leucovorin, for the frontline treatment of metastatic pancreatic adenocarcinoma.

Rutgers Cancer Institute of New Jersey has elevated 2 associate director functions to deputy director positions.

CAN-3110, an HSV-1 oncolytic viral immunotherapy candidate, has received FDA fast track designation for adult patients with recurrent high-grade glioma.

A new drug application for Dasynoc, a protein kinase inhibitor product candidate for patients with chronic myeloid leukemia, has been accepted by the FDA.

John Shen, MD, discusses the phase 1/2 APEX-01 trial of ARX517 in metastatic castration-resistant prostate cancer.

Adjuvant nivolumab significantly improved relapse-free survival vs ipilimumab in resected stage III/IV melanoma, according to 7-year minimum follow-up.

BXCL701 has been granted fast track designation for select patients with metastatic small cell neuroendocrine prostate cancer by the FDA.

Alice Mims, MD, discusses the toxicity profile and initial efficacy of emavusertib in heavily pretreated, FLT3-mutated relapsed/refractory AML.

Michael R. Bishop, MD, discusses the rationale for and key findings from the FELIX trial of obe-cel in B-cell acute lymphoblastic leukemia.

The NCCN has published the first set of treatment recommendations for neuroblastoma.

Florida Cancer Specialists & Research Institute, LLC announces the appointments of Joel Grossman, MD and Maen Hussein, MD to its Executive Board.

AlphaMedix has received breakthrough therapy designation from the FDA for use in select patients with gastroenteropancreatic neuroendocrine tumors.

Reshma Jagsi, MD, DPhil, details advances from 2023 in breast cancer radiation oncology and interventions aimed at combating disparities within oncology.

R. Lor Randall, MD, FACS, explains the next steps in ensuring adherence to clinical care guidelines in extremity sarcoma.

Radiographic and clinical progression-free survival may be surrogates for overall survival in hormone-sensitive prostate cancer clinical trials.